Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVAX is a good fit for your portfolio.
News
-
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
-
Novavax to Participate in BofA Securities 2024 Health Care Conference
-
Novavax Shares Pop Another 50% Following Sanofi Deal
-
Novavax shares more than double on Sanofi's $1.4 billion investment for combo vaccine
-
Trending: Sanofi, Novavax to Develop New Covid-19 Vaccines
-
Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi
-
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
-
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Trading Information
- Previous Close Price
- $13.01
- Day Range
- $12.68–14.80
- 52-Week Range
- $3.53–15.00
- Bid/Ask
- $14.43 / $14.50
- Market Cap
- $2.18 Bil
- Volume/Avg
- 11,349 / 12.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.13
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,992
- Website
- https://www.novavax.com
Comparables
Valuation
Metric
|
NVAX
|
DVAX
|
MRNA
|
---|---|---|---|
Price/Earnings (Normalized) | — | 132.03 | 49.47 |
Price/Book Value | — | 2.39 | 3.97 |
Price/Sales | 2.13 | 6.18 | 9.96 |
Price/Cash Flow | — | 28.63 | — |
Price/Earnings
NVAX
DVAX
MRNA
Financial Strength
Metric
|
NVAX
|
DVAX
|
MRNA
|
---|---|---|---|
Quick Ratio | 0.62 | 13.74 | 3.74 |
Current Ratio | 0.90 | 15.20 | 4.03 |
Interest Coverage | −26.84 | −3.00 | −148.54 |
Quick Ratio
NVAX
DVAX
MRNA
Profitability
Metric
|
NVAX
|
DVAX
|
MRNA
|
---|---|---|---|
Return on Assets (Normalized) | −20.87% | 3.72% | −20.12% |
Return on Equity (Normalized) | — | 6.14% | −26.85% |
Return on Invested Capital (Normalized) | — | 1.92% | −26.68% |
Return on Assets
NVAX
DVAX
MRNA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Frqblrgvbk | Lzk | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmtkhnck | Znspqzq | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ngfgdghs | Sntsq | $108.2 Bil | |
MRNA
| Moderna Inc | Nkgmxkw | Nhng | $54.0 Bil | |
ARGX
| argenx SE ADR | Zmtykfkgp | Hzm | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vfgbyyhqr | Dvsj | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nhlgcjsd | Wzxthcp | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cxdgkdzgx | Slrcfk | $14.6 Bil | |
INCY
| Incyte Corp | Djkcmvsch | Ycfdnt | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dgrhntypf | Wbmztmz | $12.3 Bil |